For employers to offer effective, accessible and affordable value-based care for their employees, they must address these four components. The post How Employers Can Leverage Value-Based Care to Drive Retention and Improved Health Outcomes for Employees appeared first on MedCity News.
Maven Clinic’s $125 million Series F funding round was led by StepStone Group and included participation from existing investors General Catalyst, Sequoia, Oak HC/FT, Icon Ventures, Dragoneer Investment Group and Lux Capital. The post Maven Clinic Snags $125M To Boost Fertility Program, Expand Value-Based Care Partnerships appeared first on MedCity News.
Pyx Health’s new condition management program will support people with conditions like diabetes, hypertension and pregnancy. The post Social Health Platform Pyx Health Unveils Condition Management Program appeared first on MedCity News.
The deadline to apply for the INVEST Pitch Perfect Contest is January 24! In addition to a business profile, Pitch Perfect winners also receive a $20,000 branding advertising package from MedCity News. The post Healthcare Startups are Running Out of Time appeared first on MedCity News.
With Donald Trump returning to the presidency, the future of Medicaid is uncertain. While Medicaid did not receive a lot of attention directly during the campaign, Trump’s first term can shed light on potential changes that could be implemented administratively without Congress.
SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system. The post Startup SiteOne Secures $100M to Forge Ahead With…
By JEFF GOLDSMITH Jeff wrote this article for Hospitals & Health Networks in the July 5, 1998 edition. He republished it this week on his substack calling it a “27th anniversary edition”. It’s an enlightening piece, but as you read it please ask yourself. What, if anything, has changed, and did anything get better?–Matthew Holt…
This is the title of a recent paper by Jiao et al. (2025). Previous studies (e.g., Goldman et al. 2013, Goldman et al. 2023) have argued for a 3-part pricing model. Under a 3-part pricing model, drugs would come to market quickly under accelerated approval with a relatively lower price. As clinical trials and other…
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology. The post At…
Explore an overview of the Mexico City Policy, which, when last in effect, required foreign NGOs to certify that they would not “perform or actively promote abortion as a method of family planning” using funds from any source (including non-U.S. funds) as a condition for receiving most U.S. government global health assistance.